Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and ...

We feel IL-13 and IL-4, addressing both those cytokines are ... is pretty interesting from our perspective and orthogonal to dupilumab. But also, subsequently we've worked out exactly why former ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

are being treated with biologics that block the IL-4/IL-13 axis (e.g., dupilumab, an anti-IL-4Rα mAb) (82, 120). Thus, the possible protective role of basophil-derived IL-4/IL-13 in MI should ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

IL-4/IL-13 stimulated release of TGFβ1, in synergy with eotaxin-3, promote fibroblast activation and differentiation into myofibroblast, ultimately leading to ECM deposition and smooth muscle cells ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Isolated cases have successfully responded to dupilumab (IL-4 and IL-3 inhibitor) and benralizumab (IL-5 inhibitor) and this is not surprising since they are T-helper 2 type cytokines inhibitors, and ...

For the first time since 2019, Illinois regulators have approved new medical conditions to qualify for medical cannabis, all centered on women’s health. Endometriosis, ovarian cysts, uterine ...